PubMed Health⌕ Search

Biomedical subjects

I Hashimoto

Publications and source records attributed to I Hashimoto.

At least 289 records · Page 16Linked to original sources
PubMed1983

Variation in virulence of Coxsackie virus B3 in the hearts of mice. I. Comparison of mortality and virus growth in the heart and other organs.

Virulence of Coxsackie virus B3 (CB3) was compared in mice between strain SK-74 isolated from a patient and strain T-70 isolated from a healthy child as well as between prototype strain Nancy and its mouse-passaged derivative strain PMH. Strain SK-74 showed a high mortality (40-80%), while strain T-70 did not induce deaths in mice (mortality: 0%). Strain PMH showed a high mortality (65-85%), but strain Nancy did not cause deaths in the mice. In agreement with the mortality trend, virus titers in the heart and other organs of mice inoculated with strain SK-74 and PMH were higher than those in mice inoculated with T-70 and Nancy strains. Since virus titers in the heart remained higher than those in other organs, the heart was regarded as the main organ in which CB3 could replicate and induce cell degeneration. The present results suggest that a marked variation in virulence in the hearts of mice among CB3 strains occurred and that passage through the hearts of mice enhances the virulence of CB3 in the hearts of mice.

Animals↗
PubMed1983

[Mucohistochemical studies of CEA producing and non-producing stomach cancers].

In this report, 141 patients with gastric cancer were studied histochemically. Tissue CEA was stained by the CEA-PAP method and the gastric cancer was classified into CEA-producing (96 cases, 68.1%) and CEA non-producing gastric cancer (45 cases, 31.9%). Histologically, CEA-producing gastric cancer was well differentiated adenocarcinoma and CEA non-producing gastric cancer was chiefly undifferentiated carcinoma. PAS, pH 2.5 Alcian-blue, High Iron Diamine, Alkaline-PAS, and Concanavalin A paradoxical stain were applied to specimens from each type of gastric carcinoma. Mucosubstances of CEA-producing gastric cancer were positive for A-B, HID, AL-PAS and CPS III-1; those of CEA non-producing gastric cancer were positive for PAS and CPS III-s, but negative for A-B, HID and A1-PAS. These results suggest that CEA-producing gastric cancer arises from intestinal metaplasia of gastric mucosa and that CEA non-producing gastric cancer arises from the gastric mucosa itself.

Adenocarcinoma↗
PubMed1983

[Specific active immunotherapy of murine methylcholanthrene-induced sarcoma using a partially purified soluble tumor specific transplantation antigens].

Immunotherapeutic effects of soluble tumor specific transplantation antigens (TSTA) were studied, Crude 3M KC1 extract of C3H/He methylcholanthrene-induced sarcoma (F tumor) was purified by preparative isoelectric focusing (pIEF). The immunoprotective fraction (Fr. 15, pI 5.7-6.0) possessed about 50 fold greater activity than the crude 3M KC1 extract. Three weekly injections of optimal immunoprotective dose of Fr. 15 retarded the outgrowth of F cells and decreased the outgrowth and tumor incidence of rechallenged inoculation in mice completely resected established 1 cm tumor. Weekly injections of Fr. 15 resulted in decreased local recurrences. This therapeutic effect was immunologically specific. Fr. 15 alone did not show the therapeutic effects on the established tumor, but combined treatment with cyclophosphamide gave the increased survivals. A metastatic variant cell line (F-4) metastasized to the lung spontaneously after the resection of primary subcutaneous tumor. Therapeutic injections of Fr. 15 decreased the rates of spontaneous pulmonary metastasis of F-4. Since cross-immunoprotection tests revealed that F and F-4 share the common TSTA, the therapeutic effect of Fr. 15 upon pulmonary metastases might be due to improved host's specific immunity.

Animals↗
PubMed1983

The role of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease.

Myocarditis in athymic BALB/c-nu/nu (nu/nu) mice infected with Coxsackie virus B3 was studied to determine whether inflammatory mononuclear cell infiltration was produced by transfer of spleen cells ob BALB/c-nu/+ (nu/+) mice infected with the same virus. In addition, spleen cells of uninfected nu/+mice were transferred into athymic nu/nu mice infected with Coxsackie virus B3. Athymic nu/nu mice infected with Coxsackie virus B3 after transfer of spleen cells of nu/+ mice infected with the same virus developed marked to moderate myocarditis with inflammatory mononuclear cell infiltration. However, athymic nu/nu mice infected with Coxsackie virus B3 after transfer of spleen cells of uninfected nu/+ mice developed moderate to mild degeneration or necrosis of the muscle fibres, although mild mononuclear cell infiltration was found in only one mouse. The incidence of myocardial lesions of athymic nu/nu mice infected with Coxsackie virus B3 after transfer of infected-spleen cells of nu/+ mice was about the same is that in infected nu/+ mice after transfer of spleen cells of uninfected nu/+ mice. However, degrees in the intensity of the muscular changes and inflammatory mononuclear cell infiltration in the former was significantly greater than that in the latter. The results show, therefore, that Coxsackie virus B3 infection stimulated production of cytotoxic activity in the spleen which was evident on Day 6. From the present results, it is confirmed that myocarditis in mice infected with Coxsackie virus B3 is thymus-dependent, supporting previous investigations.

Animals↗
PubMed1983

[Clinical study of cefmenoxime in acute peritonitis: clinical effect and tissue concentration of cefmenoxime].

A new antibiotic drug of cephalosporin group, with marked resistance of beta-lactamase, cefmenoxime (CMX) for parenteral use was tested in 15 patients with acute peritonitis. CMX in a dose of 500 mg was given intramusculary before the operation, to 8 cases with appendicitis, and 2 cases with intestinal obstruction. In 3 cases with appendicitis and a case with intestinal perforation, CMX in a dose of 500-1,000 mg was given by intravenous injection before or during the operation. And in a case with appendicitis, CMX in a dose of 1 g was given by intravenous drip infusion before the operation. Tissue specimens of different sites or body fluids were taken during the operation and from the removed organs. The materials of purulent ascites were subsequently taken at intervals. Determination of CMX concentration was performed according to cup bioassay method with Proteus mirabilis ATCC 21100 strain. The peak of CMX concentration in purulent ascites of patient with panperitonitis for intestinal perforation was 39.5 microgram/ml at 41 minutes after 1 g intravenous administration. Concentration of CMX in pus in the appendix was 52.5 microgram/ml at 20 minutes after 1 g intravenous administration. In 15 patients with acute peritonitis, 11 patients were given CMX in a dose of 500 mg by intramuscular administration twice a day, and the serious 4 patients were given in a dose of 500 mg to 1 g by intravenous drip infusion twice a day. Clinical response was excellent in 10 cases, good in 5 cases, fair and poor were none.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1983

[Clinical effect of cefmenoxime on cholecystitis; its clinical efficacy and tissue concentration].

A new antibiotic drug of cephalosporin, with marked resistance to beta-lactamase, cefmenoxime (CMX) for parenteral use was used in 14 patients with acute or subacute cholecystitis and cholangitis. CMX was given by intramuscular or intravenous drip infusion at a daily dose of 500 mg to 2 g. Clinical response was excellent in 3 cases, good in 10 cases, fair in 1 case and poor in none. Any clinical adverse effect was not recognized. CMX in a dose of 500 mg was given by intramuscular administration before the operation to 8 patients, and in 7 cases CMX in a dose of 1 g was given by intravenous administration before or during the operation. Tissue specimens of different sites were taken from the removed organs. The materials of A-bile and B-bile were subsequently taken at intervals. CMX concentrations in the A-bile increased after intramuscular injection and reached to peak 2 hours, then declined very slowly. CMX concentrations in the A-bile after intravenous administration reached to peak at 1 hour, then declined very slowly, too. CMX concentration in the B-bile reached to high level of the concentration comparative quickly after intramuscular and intravenous administration, and it was thought to be excreted through the gallbladder wall. CMX concentration in the gallbladder wall was directly proportional to the degree of pathological changes of the inflammation. On the CMX concentration in patients with cholecystitis and cholangitis, the concentration in A-bile, B-bile and gallbladder wall were observed higher than the MIC of CMX for pathogenic Gram-negative bacilli. CMX therefore will be a very useful drug when used for chemotherapy of the infectious diseases of the biliary tract.

Acute Disease↗
PubMed1983

[Clinical evaluation of the method to determine antibiotic concentrations in small amounts of samples].

Concentrations of cefotiam (CTM) in the exudate after abdominal operation were studied. The exudates were collected by 6 mm paper discs and the antibiotic concentrations were determined by the paper disc method using Proteus rettgeri ATCC 9250 as test organism. Comparison between agar well and paper disc assay for CTM in ascites specimens showed good correlation. Two grams of CTM was intravenously given to the patients after abdominal operations. The concentration of CTM in the exudate for 6 hours after injection was 0.4--14.2 micrograms/ml and this value exceeded the antibacterial level of CTM. It is, therefore, concluded that CTM will be effective for the postoperative prophylaxis.

Adult↗
PubMed1983

[Chemotherapy of gastric cancer patients with hepatic metastases].

The effect of post-operative adjuvant chemotherapy on the prognosis of gastric cancer patients with hepatic metastases was evaluated. Forty-two cases were classified into-following four groups: (A) no chemotherapy, (B) short-term chemotherapy (5 g of 5 FU i.v., or 1/2 FM (F') C alone), (C) long-term chemotherapy (1/2 MF (F') C plus 0.6 g of FT-207 per os), (D) long-term chemotherapy (1/2 MF (F') C plus 1.5 g/day of FT-207 per annum). Six, nine, twelve month survival rates of patients in group (D) was significantly higher than group (A). Mean survival time of each group was: (A) 4.7, (B) 5.2, (C) 5.7 and (D) 9.1 months. Correlation between the survival time and the total dose of FT-207 was observed. Total dose of FT-207 in group (D) was 129.3 g and 60.8 g in group (C). These may reflect the results that the rectal administration was more effective than the oral administration of FT-207.

Administration, Oral↗
PubMed1983

[UFT concentration in various tissues from cancer patients].

UFT, an antitumor drug combined of Tegafur 1 and Uracil 4, was administered preoperatively to 23 cancer patients including 11 cases of breast, 8 of gastric, 2 of colon and 2 of other cancers. Tissue specimens of different sites and serum samples were collected during the operation: cancer tissues, normal breast, normal gastric, colon or rectal wall, lymph nodes and subcutaneous fatty tissues, etc., and concentrations of tegafur (FT), 5-fluorouracil (5-FU) and uracil were studied using HCLP or GC-MF methods. In most cases, 5-FU and uracil concentrations detected in cancer tissues from the patients were higher than those found in non cancer sites. FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported. Patients with benign tumor having mastopathy or were reported to show very low 5-FU concentration in tissue which was almost undetectable. From the above results, it has been suggested that UFT is a useful drug in cancer chemotherapy.

Administration, Oral↗
PubMed1983

Genetic counseling for skin diseases. A statistical analysis of 182 cases.

A statistical study was carried out on 182 cases who seeked out genetic counseling about skin diseases. The size of the latent demand for the counseling was assessed to be as much as 3.0% of the outpatients. Most clients were in their twenties. A representative consultand was the patient's child or sibling. The main diseases in question were cleft lip and palate (16%), nevus pigmentosus (12%), Recklinghausen's diseases (8%) and psoriasis (8%). Estimation of the recurrence risk was impossible in 3%, approximate in 54% and accurate in 43%. This defective estimation is due to the insufficiency of the available genetic data, e.g. carrier frequency, penetrance rate, contraction rate by age, etc. The high-risk cases were found to be 36%. In 9 cases (5% of all the counselings) the client decided to avoid reproduction. In 30 cases (16%), the clients asked for counseling after having conceived or given birth to a consultand. They were thought to be too late from the standpoint of prophylaxis of inherited diseases. Our conclusion is that genetic counseling offers some measure of disease prevention and therefore will become an essential branch or dermatology in the future.

Adolescent↗
PubMed1983

[Clinical effect of intramuscular injection of cefpiramide in infections associated with surgery].

The authors treated a total of 23 patients (15 were outpatients, 8 were hospitalized), employing an injectable preparation of cefpiramide (CPM) a new antibiotic of the cephems. Included in this total were 10 cases of acute infectious diseases of skin and soft tissues, 5 cases of acute localized peritonitis, 5 cases of acute urinary tract infection and 3 cases of acute and subacute cholecystitis. To 15 cases of outpatients, CPM in a dose of 500 mg were given by intramuscular injection once a day, and to 8 cases of hospitalized patients were given 500 mg of CPM by intramuscular injection twice a day. The duration were 3 to 15 days. The clinical efficacy obtained was excellent in 4 cases, good in 17 cases, and fair in 2 cases. In no case was CPM found to be completely ineffective. Clinical adverse effect was not recognized. Therefore, CPM will be a useful drug when used for chemotherapy of acute or subacute infectious diseases on surgical field following intramuscular administration.

Acute Disease↗
PubMed1983

[Immunological evaluation of splenectomy in tumor-bearing mice].

The effect of splenectomy upon neoplastic outgrowth was examined after inoculation of methylcholanthrene-induced C3H/He murine tumors. Three days or 20 days after tumor inoculation, splenectomy resulted in significant retardation of tumor growth when compared with sham operation, while splenectomy 6, 9, 15 days after tumor inoculation did not alter the tumor outgrowth. These results suggest that spleen might have immunologically negative element in early or late stage of tumor burden. In fact, spleen cells from mice bearing MCA-F tumors for 3 days or 30 days nonspecifically facilitated the tumor outgrowth in Winn assay. The non-specific tumor-enhancing cells were radioresistant (700 rads), capable of phagocytizing carbonyl-iron and adherent to plastic dish suggesting those were tumor enhancing macrophages. On the other hand, spleen cells from tumor-bearing mice for 9 to 15 days specifically reduced the tumor growth in Winn assay, and those cytotoxic cells were radio-sensitive (700 rads) T cell population.

Animals↗
PubMed1983

[Clinical studies on gentamicin for infectious diseases following intravenous drip infusion].

An antibiotic drug of aminoglycoside group, gentamicin (GM) for parenteral use was used to 14 hospitalized patients; 5 with acute or subacute cholecystitis, 6 with acute peritonitis (4 cases were due to acute appendicitis, a case was torsion of right ovarian cyst and a case was cecal CROHN's disease), 1 with fistula ani and abscess, and 2 with localized peritonitis after gastrectomy due to gastric ulcer. GM in a dose of 60 mg were administered by intravenous drip infusion for 1 to 2 hours, twice a day for 4 to 12 days. To the cases of biliary tract infection, GM was treated for preoperative chemotherapy and to the other cases GM was treated for postoperative chemotherapy. Clinical response was excellent in 7 cases, good in 6 cases, fair in 1 case and poor in none. No adverse effect was observed. The organisms were isolated in 7 cases, 7 were Escherichia coli, 2 were Klebsiella pneumoniae and 3 were Bacteroides fragilis. The MICs for GM were 0.78--1.56 micrograms/ml in 10(8) and 10(6) cells/ml, except B. fragilis. Before the operation of above cases, GM in a dose of 60 mg (a case was 40 mg) were administered by intravenous drip infusion for 1 to 2 hours in 7 cases (3 biliary tract infection, 2 acute peritonitis and 2 gastric ulcer) and 7 cases by intramuscularly. The materials of common duct bile, gall bladder bile, gall bladder wall, the appendix and other tissues, ascites and serum samples were taken during the operation. GM concentration was measured by bioassay method with Bacillus subtilis ATCC 6633 as test organism. GM concentrations in bile and gall bladder wall after intravenous drip infusion were higher than those after intramuscular administration. In the appendicitis with localized peritonitis, GM concentration in the appendix wall with catarrhal appendicitis was 0.90 microgram/g after intramuscular administration. In the cases with diffuse peritonitis and catarrhal appendicitis, GM concentrations in appendixes were 1.18 micrograms/g and 1.37 micrograms/g after intravenous drip infusion. Therefore, it was supposed that GM could be used safety and usefully by intravenous drip infusion than that by intramuscular administration.

Acute Disease↗
PubMed1983

[Role of the spleen in OK-432 immunotherapy and characterization of effector cells].

The mechanism of anti-tumor effect of OK-432 was examined in C3H/He mice transplanted with methylcholanthrene induced fibrosarcomas. Tumor growth was significantly reduced in mice treated with OK-432 daily for 7 days after tumor inoculation. Tumor growth was significantly reduced in Sham-operated mice treated with OK-432 when compared to untreated controls. On the other hand, splenectomized mice failed to respond to OK-432 immunotherapy, suggesting the spleen is an essential organ in host responsiveness to this immunostimulant. Further dissection of the mechanism of OK-432 immunotherapy was achieved by Winn assay with spleen cells taken from mice inoculated with MCA-F (1 X 10(5) cells) and OK-432 for 7 days. Spleen cells from tumor-bearing mice which had been treated with OK-432 further reduced the tumor growth compared with spleen cells from tumor-bearer and such cytotoxic activity was reduced by the spleen cells with treatment of anti-Thy 1. 2 serum plus complement or by 700 rads irradiation before Winn assay, suggesting that OK-432 generated cytotoxic T cell population in vivo.

Animals↗
PubMed1983

[Study of mechanisms of increasing serum RNase].

In 1976 Reddi et al. reported increase of serum Ribonuclease (RNase) in pancreatic cancer patients. In this study, the increase in serum RNase activity was observed in patients with pancreatic cancer, coincided with the report by Reddi et al. The increase was also observed in patients with advanced gastric cancer. Especially, in patients with cancer invasion into pancreas, high value was obtained. Patients with other cancers showed the elevation of RNase activities. Thus, the elevation of serum RNase level is not specific only to patients with pancreatic cancer. An selectric focusing test showed no distinguishable difference in patients with pancreatic cancer and healthy persons. In mice with transplanted tumor of pancreas, serum RNase increased. Simultaneously, histological dilatation of pancreatic ducts and destruction of acinus were observed. When pancreas was occupied by tumor, serum RNase was decreased. These results suggest that RNase is not produced by cancer cell but is released from pancreas itself.

Animals↗